Form 4: Plus Therapeutics Director Reports Stock Transaction
Insider Transaction (Form 4)
Ronald Asbury Andrews, a Director of Plus Therapeutics, Inc., reported multiple transactions in common stock on October 1, 2026.
Summary
- Option exercise/conversion: acquired 921 Common Stock on October 1, 2026; holds 1,843 after (Direct).
- Option exercise/conversion: disposed of 921 Restricted Stock Units on October 1, 2026; holds 1,843 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Ronald Asbury Andrews — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-01 | Option exercise/conversion | Common Stock | 921 | — | — | 1,843 |
| 2026-10-01 | Option exercise/conversion | Restricted Stock Units | 921 | — | — | 1,843 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-01 | Option exercise/conversion (921 shares) |
| 2026-10-01 | Option exercise/conversion (921 shares) |
Keywords
insider transaction, Form 4, CNSY, CERENOME, INC., neutral, Ronald Asbury Andrews
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.